{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:09:08Z","timestamp":1792098548764,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.lungcan.2016.05.029","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T16:47:11Z","timestamp":1464713231000},"page":"106-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5601-4119","authenticated-orcid":false,"given":"Andrew L.","family":"Laccetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandi L.","family":"Pruitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan A.","family":"Halm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.05.029_bib0005","series-title":"Oxford American Oncology Library: Lung Cancer","article-title":"Chapter 8: locally advanced non-Small cell lung cancer","author":"Gerber","year":"2013"},{"issue":"41","key":"10.1016\/j.lungcan.2016.05.029_bib0010","first-page":"9","article-title":"Cancer statistics","volume":"6","author":"Siegel","year":"2014","journal-title":"CA : Cancer J. Clin."},{"issue":"9687","key":"10.1016\/j.lungcan.2016.05.029_bib0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.lungcan.2016.05.029_bib0020","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1200\/JCO.2005.55.405","article-title":"Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol","volume":"23","author":"Belani","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2016.05.029_bib0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol."},{"issue":"35","key":"10.1016\/j.lungcan.2016.05.029_bib0030","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1200\/JCO.2008.17.7840","article-title":"Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S Oncology","volume":"26","author":"Hanna","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2016.05.029_bib0035","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2007.14.4824","article-title":"Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023","volume":"26","author":"Kelly","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2016.05.029_bib0040","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.lungcan.2016.05.029_bib0045","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA: J. Am. Med. Assoc."},{"issue":"6","key":"10.1016\/j.lungcan.2016.05.029_bib0050","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2001.19.6.1728","article-title":"Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment","volume":"19","author":"Lara","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2016.05.029_bib0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JOP.2013.001119","article-title":"The national cancer institute-american society of clinical oncology cancer trial accrual symposium: summary and recommendations","volume":"9","author":"Denicoff","year":"2013","journal-title":"J. Oncol. Pract."},{"issue":"2","key":"10.1016\/j.lungcan.2016.05.029_bib0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0895-4356(97)00240-0","article-title":"A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group","volume":"51","author":"Fuks","year":"1998","journal-title":"J. Clin. Epidemiol."},{"issue":"11","key":"10.1016\/j.lungcan.2016.05.029_bib0065","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju302","article-title":"Impact of prior cancer on eligibility for lung cancer clinical trials","volume":"106","author":"Gerber","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.lungcan.2016.05.029_bib0070","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ejcts.2008.08.004","article-title":"Multiple independent primary cancers do not adversely affect survival of the lung cancer patient","volume":"34","author":"Aguilo","year":"2008","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"4","key":"10.1016\/j.lungcan.2016.05.029_bib0075","first-page":"1152","article-title":"Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival","volume":"127","author":"Duchateau","year":"2005","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.lungcan.2016.05.029_bib0080","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/thx.2005.051615","article-title":"Carcinoma Cooperative Group of the Spanish Society of, S., Thoracic, Previous tumour as a prognostic factor in stage I non-small cell lung cancer","volume":"62","author":"Lopez-Encuentra","year":"2007","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.lungcan.2016.05.029_bib0085","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0169-5002(01)00408-1","article-title":"Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis","volume":"35","author":"Liu","year":"2002","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2016.05.029_bib0090","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S1010-7940(00)00571-6","article-title":"Lung cancer following previous extrapulmonary malignancy","volume":"18","author":"Massard","year":"2000","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"4","key":"10.1016\/j.lungcan.2016.05.029_bib0095","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv002","article-title":"Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual","volume":"107","author":"Laccetti","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"8 Suppl","key":"10.1016\/j.lungcan.2016.05.029_bib0100","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med. Care"},{"key":"10.1016\/j.lungcan.2016.05.029_bib0105","series-title":"SEER Cancer Statistics Review, 1975\u20132007","author":"Altekruse","year":"2010"},{"key":"10.1016\/j.lungcan.2016.05.029_bib0110","series-title":"National Cancer Institute SEER Coding and Staging Manual","author":"Adamo","year":"2015"},{"key":"10.1016\/j.lungcan.2016.05.029_bib0115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/1471-2407-14-272","article-title":"Second primary cancer risk\u2014the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study","volume":"14","author":"Coyte","year":"2014","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.lungcan.2016.05.029_bib0120","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.05.029_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2013.06.009","article-title":"Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer","author":"Ahn","year":"2013","journal-title":"Clin. Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2016.05.029_bib0130","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/jnci\/djn175","article-title":"Evaluation of trends in the cost of initial cancer treatment","volume":"100","author":"Warren","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.lungcan.2016.05.029_bib0135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.lungcan.2016.05.029_bib0140","author":"National Cancer Institute"},{"issue":"1","key":"10.1016\/j.lungcan.2016.05.029_bib0145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1475-6773.2009.01051.x","article-title":"The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study","volume":"45","author":"Koroukian","year":"2010","journal-title":"Health Serv. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2016.05.029_bib0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cllc.2012.03.008","article-title":"Identifying barriers associated with enrollment of patients with lung cancer into clinical trials","volume":"14","author":"Horn","year":"2013","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.05.029_bib0155","article-title":"Second primary cancers in the vaud and neuchatel cancer registries","author":"Levi","year":"2014","journal-title":"Eur. J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.lungcan.2016.05.029_bib0160","first-page":"561","article-title":"Cancer survivors in the United States : prevalence across the survivorship trajectory and implications for care, cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research","volume":"22","author":"de Moor","year":"2013","journal-title":"Am. Soc. Prev. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2016.05.029_bib0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: u.S. preventive services task force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2016.05.029_bib0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jnci\/90.1.63","article-title":"Survival of patients with colorectal carcinoma: effect of prior breast cancer","volume":"90","author":"Sankila","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.lungcan.2016.05.029_bib0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jnci\/95.5.341","article-title":"Chemotherapy for elderly patients with advanced non-small cell lung cancer","volume":"95","author":"Bunn","year":"2003","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T01:35:13Z","timestamp":1556328913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216303555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":35,"alternative-id":["S0169500216303555"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.05.029","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}